About the webinar:
The mouse stands as a critical tool in advancing preclinical immunological research. However, disparities in immunological signaling cascades and the innate immune response between mice and humans can lead to non-translatable preclinical results. The development of complex humanized immune system (HIS) mice addresses this issue with predominant success in immuno-oncology research applications, and limited validation in autoimmune disease studies so far.
Toll-like receptors (TLRs) play a central role in innate human response, but species differences can obscure preclinical investigations targeting human TLR drug discovery. This webinar will delve into the effective utilization of a human-specific TLR4 agonist in HIS mice as a platform for drug discovery focused on the human innate response.
Explore the development of a preclinical mouse model for profiling therapeutics directed towards targets in the human TLR4 pathway, building upon a HIS mouse with human myeloid and lymphoid cells. Learn how the use of a human-specific test molecule in a system with the presence of primarily human immune cells minimizes the contribution of murine TLR4 signaling and allows study of human targets in an in vivo preclinical model.
View this webinar to learn about:
- Strategies to overcome species limitations in preclinical in vivo studies of innate immunity
- How HIS mice can be used to profile drugs which do not cross-react with analogous mouse targets
- Unique considerations related to HIS mice which must be considered when developing model systems, including donor effects and engraftment kinetics
- Validation of a model to study pharmacodynamic effects of immune-modulating drugs on human innate immune signaling
